X
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
Alfasigma completed acquisition of Jyseleca (filgotinib), which provides European and UK Marketing Authorizations. It is used for the treatment of moderate to severe rheumatoid arthritis.
Lead Product(s): Filgotinib
Therapeutic Area: Immunology Product Name: Jyseleca
Highest Development Status: ApprovedProduct Type: Small molecule
Recipient: Galapagos
Deal Size: $184.9 million Upfront Cash: $54.3 million
Deal Type: Acquisition January 31, 2024
Details:
The agreement aims to transfer Galapagos’ Jyseleca (filgotinib maleate) business to Alfasigma, marking a significant milestone in its transformation into an innovative biotechnology company with a pipeline aimed for immunology and oncology.
Lead Product(s): Filgotinib
Therapeutic Area: Immunology Product Name: Jyseleca
Highest Development Status: ApprovedProduct Type: Small molecule
Recipient: Galapagos
Deal Size: $229.7 million Upfront Cash: $54.7 million
Deal Type: Agreement January 02, 2024
Details:
Through the acquisition, Alfasigma adds Ocaliva (obeticholic acid), a farnesoid X receptor agonist approved in the United States for the treatment of primary biliary cholangitis in combination with ursodeoxycholic acid in adults with an inadequate response to UDCA.
Lead Product(s): Obeticholic Acid
Therapeutic Area: Hepatology (Liver, Pancreatic, Gall Bladder) Product Name: Ocaliva
Highest Development Status: ApprovedProduct Type: Small molecule
Recipient: Intercept Pharmaceuticals
Deal Size: $794.0 million Upfront Cash: $794.0 million
Deal Type: Acquisition November 08, 2023
Details:
Through the acquisition, Alfasigma adds Ocaliva (obeticholic acid), a farnesoid X receptor agonist approved in the United States for the treatment of primary biliary cholangitis in combination with ursodeoxycholic acid in adults with an inadequate response to UDCA.
Lead Product(s): Obeticholic Acid,Ursodeoxycholic Acid
Therapeutic Area: Hepatology (Liver, Pancreatic, Gall Bladder) Product Name: Ocaliva
Highest Development Status: ApprovedProduct Type: Small molecule
Recipient: Intercept Pharmaceuticals
Deal Size: $794.0 million Upfront Cash: $794.0 million
Deal Type: Acquisition September 26, 2023
Details:
Bentracimab is a new human monoclonal antibody fragment which in previous clinical studies has shown an immediate and prolonged reversal of the antiplatelet effects of Brilinta® / Brilique® (ticagrelor).
Lead Product(s): Bentracimab
Therapeutic Area: Hematology Product Name: PB2452
Highest Development Status: Phase IIIProduct Type: Large molecule
Recipient: PhaseBio Pharmaceuticals
Deal Size: $245.0 million Upfront Cash: $20.0 million
Deal Type: Acquisition June 22, 2021
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
